-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FptMPrfD9p28nl00Ojxe5I8YTA0jqidJwwDbHxmNzidAWZSqCorO1bDYW2eIBFv6 rMYMtvJNIyZMpul8Cp7uRg== 0000936392-98-001318.txt : 19981005 0000936392-98-001318.hdr.sgml : 19981005 ACCESSION NUMBER: 0000936392-98-001318 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19981002 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIDAK PHARMACEUTICALS CENTRAL INDEX KEY: 0000858803 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330314804 STATE OF INCORPORATION: CA FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: SEC FILE NUMBER: 000-18734 FILM NUMBER: 98720024 BUSINESS ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 93121-3016 BUSINESS PHONE: 6195580364 MAIL ADDRESS: STREET 1: 9393 TOWN CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 93121-3016 DEFA14A 1 ADDITIONAL DEFINITIVE PROXY MATERIAL 1 SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy Statement [X] Definitive Additional Materials [ ] Soliciting Material Pursuant to sec.240.14a-11(c) or sec.240.14a-12 LIDAK PHARMACEUTICALS - -------------------------------------------------------------------------------- (Name of Registrant as Specified In Its Charter) - -------------------------------------------------------------------------------- (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): [X] No fee required. [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: [ ] Fee paid previously with preliminary materials. [ ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: 2 [LIDAK LOGO] October 1, 1998 To Our Shareholders: This is an exciting time for the Company as we approach the Food and Drug Administration's decision regarding marketing approval of our first product, n-docosanol 10% cream. I would like to take this opportunity to provide an update for you. As those following the Company's progress will recall, when we filed the n-docosanol new drug application with the FDA in late December 1997, the filing was placed on a "12 month track", implying a decision in the fourth quarter of this year. During the last several months, we have been preparing our plan for product launch, which continues to be our "Number One" priority. As part of our product launch plan for n-docosanol, we are working to complete commercial agreements with our contract drug and product manufacturers and warehousing and distribution companies, to prepare as much as practicable in advance of the FDA's decision. Additionally, we are working on co-promotion opportunities to supplement our marketing campaign. Earlier this year, we presented a strategic plan at our annual shareholders' meeting. We have been aggressively implementing this plan. Let me now share some of our progress with you. As with any major undertaking, the most important factor is the people who do the work. We are fortunate because in addition to our excellent technical staff, several talented and experienced managers have recently joined our management team. In July, Gregory Hanson became the Company's Chief Financial Officer. Greg brings us a wealth of experience of having served as CFO at several technology companies. In September, David Hansen became Vice President of Sales and Marketing. David has considerable experience in successfully launching new pharmaceutical products and will play an important role in the commercialization of n-docosanol. We are pleased to have both executives with us during this important phase of the Company's growth. Also in September, the Company retained The Dilenschneider Group, an investor relations agency in New York, to communicate news to Wall Street. BGM Health Communications, a Los Angeles based, medical/healthcare marketing communications agency, was retained to help build the commercialization plan for n-docosanol as we prepare to launch this product to the health care professional and consumer markets. As fiscal year 1999 progresses, we intend to investigate in-licensing opportunities to help fill our product pipeline. In summary, we believe that the execution of our strategic plan is on track for the coming new fiscal year. I would like to thank our shareholders for their loyalty and confidence in us as the Company achieves transition with its new strategic plan. We fully intend to build long-term shareholder value as your company moves ahead. Sincerely, /s/ Gerald J. Yakatan --------------------------- Gerald J. Yakatan, Ph.D. Chief Executive Officer -----END PRIVACY-ENHANCED MESSAGE-----